Immune regulation in Epstein-Barr virus-associated diseases - PubMed (original) (raw)

Review

Immune regulation in Epstein-Barr virus-associated diseases

R Khanna et al. Microbiol Rev. 1995 Sep.

Abstract

Epstein-Barr virus (EBV) is a member of the human herpesvirus family and, like many other herpesviruses, maintains a lifelong latent association with B lymphocytes and a permissive association with stratified epithelium in the oropharynx. Clinical manifestations of primary EBV infection range from acute infectious mononucleosis to an asymptomatic persistent infection. EBV is also associated with a number of malignancies in humans. This review discusses features of the biology of the virus, both in cell culture systems and in the natural host, before turning to the role of the immune system in controlling EBV infection in healthy individuals and in individuals with EBV-associated diseases. Cytotoxic T cells that recognize virally determined epitopes on infected cells make up the major effector arm and control the persistent infection. In contrast, the options for immune control of EBV-associated malignancies are more restricted. Not only is antigen expression restricted to a single nuclear antigen, EBNA1, but also these tumor cells are unable to process EBV latent antigens, presumably because of a transcriptional defect in antigen-processing genes (such as TAP1 and TAP2). The likelihood of producing a vaccine capable of controlling the acute viral infection and EBV-associated malignancies is also discussed.

PubMed Disclaimer

Cited by

Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines.
Khanna R, Burrows SR, Neisig A, Neefjes J, Moss DJ, Silins SL. Khanna R, et al. J Virol. 1997 Oct;71(10):7429-35. doi: 10.1128/JVI.71.10.7429-7435.1997. J Virol. 1997. PMID: 9311821 Free PMC article.
Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.
Tedeschi R, Pin E, Martorelli D, Bidoli E, Marus A, Pratesi C, Bortolin MT, Zanussi S, Vaccher E, Dolcetti R, De Paoli P. Tedeschi R, et al. Clin Vaccine Immunol. 2007 Apr;14(4):435-41. doi: 10.1128/CVI.00466-06. Epub 2007 Feb 28. Clin Vaccine Immunol. 2007. PMID: 17329446 Free PMC article.
HIV Associated Intra-oral Burkitt's Lymphoma: A Case Report.
Pinisetti S, Nalabolu GR, Uvr C, Tadi DP. Pinisetti S, et al. J Clin Diagn Res. 2013 Dec;7(12):3088-9. doi: 10.7860/JCDR/2013/6715.3862. Epub 2013 Dec 15. J Clin Diagn Res. 2013. PMID: 24551737 Free PMC article.
X linked lymphoproliferative disease in a United Kingdom family.
Arkwright PD, Makin G, Will AM, Ayres M, Gokhale DA, Fergusson WD, Taylor GM. Arkwright PD, et al. Arch Dis Child. 1998 Jul;79(1):52-5. doi: 10.1136/adc.79.1.52. Arch Dis Child. 1998. PMID: 9771253 Free PMC article.
Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory.
Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB. Steven NM, et al. J Exp Med. 1996 Nov 1;184(5):1801-13. doi: 10.1084/jem.184.5.1801. J Exp Med. 1996. PMID: 8920868 Free PMC article.

References

1. EMBO J. 1986 Oct;5(10):2599-607 - PubMed
1. J Virol. 1990 May;64(5):2126-34 - PubMed
1. J Gen Virol. 1988 Aug;69 ( Pt 8):2093-6 - PubMed
1. Int J Cancer. 1985 Jan 15;35(1):35-42 - PubMed
1. J Gen Virol. 1981 Aug;55(Pt 2):315-31 - PubMed

Immune regulation in Epstein-Barr virus-associated diseases - PubMed (original) (raw)